- Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria
- In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective
- The positive Phase 2b results for the next generation antimalarial therapy support continued development of the combination
Basel, September 29 …